Start-ups: „Deutschland hat kein Kapital-, sondern ein Gründerproblem“
Philipp Baaske hat sein Biotechunternehmen ohne Wagniskapital aufgebaut – und schon nach zwei Jahren Profit gemacht. Dass es Gründern an Kapital mangelt, hält er für vorgeschoben.
Philipp Baaske, a man with shoulder-length hair, sits in his newly acquired office at the Ludwig-Maximilians-University in Munich. Not long ago, he was the CEO of his biotech startup, Nanotemper, which creates biophysically based measuring instruments for basic research, biotechnology, and the pharmaceutical industry. However, in May 2025, Baaske received a call from the President of LMU, who wanted him to become the Vice President for Entrepreneurship.
The job entailed streamlining bureaucracy to facilitate more spin-offs. "That was high risk," Baaske admits. Others had warned him that the LMU and bureaucracy would be different from the startup world, and he might fail. But Baaske has never been afraid of financial matters. Consequently, he left Nanotemper as CEO and now serves as a shareholder and so-called Executive Chairman, pursuing a completely different goal.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Start-ups: "Germany has no capital problem, but a founder problem" handelsblatt.com
